HC100©

HC100© is an exclusive infusion technology device which improves the quality of life for those patients receiving infusions of vesicant and irritant drugs such as chemotherapeutics. HC100© permits a safe and cost convenient infusion therapy which reduces risks and injuries to all patients in need of vesicant and irritant drugs infusions.

    Vascular damage

    Vascular damage induced by ions and cytotoxic drugs are frequent events and known as chemical phlebitis. Swissmedendi’s infusion technology device HC100© assist in the prevention of
    • Loss of endothelial cells
    • Inflammatory cells infiltration
    • Edema
    • Thrombosis
    • Sclerosis
    Injuries can be proximal or distal to the catheter tips and usually irritates the venousendothelial cells over a longer distance from the catheter tip.

    Unique Methods and Technology

    Swissmedendi owns unique technology able to protect patients’ veins from vesicant agents causing irreversible endothelial damage; saving lives and reducing risks and injuries to patients and offering enormous cost saving.

    Devices

    All our devices are disposable non invasive class IIa (Europe) and class 2 (USA). These do not vary therapeutics administration protocols, infusion speed or drug concentration.

    Employing the technology will help hospitals to manage costs, enable doctors to focus more on their patients’ needs, and improve patients’ quality of life.

    The devices are easy to use and adaptable to devices currently in use.

     

    Intellectual Property

    Patents Granted.
    CE certified #1715/MDD IMQ 01/10/2014.

    [2-1] Marc Stranz, understanding pH and osmolarity, INS Phoenix 2008.

    Contact us

    Our Location

    Swiss Medendi SA
    Via Lucino 28

    CH-6932 Breganzona

    8 + 7 =